THOU DOTH PORTEST — Protests are set to pop up around the Bay State this weekend, capping off a week of tension between the ...

Is a longevity pill on the horizon? Harvard Medical School professor David Sinclair certainly thinks so – while staring down ...

The growing prevalence of uterine fibroids, especially among women of reproductive age, is fueling the demand for treatment devices. This surge is fu ...

The Veeva Commercial Summit 2025 highlighted the latest innovations connecting sales, marketing and medical — including Veeva AI.

Starting fecal immunochemical testing (FIT) at ages 40 to 49 was associated with reduced colorectal cancer (CRC) incidence ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug development and research, commercial strategy, and ...